Brief: Silo Pharma's SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis
16/10/2023 14:03
Oct 16 (Reuters) - Silo Pharma Inc SILO.O :
* SILO PHARMA’S SPU-21 PEPTIDE SHOWS POSITIVE RESULTS
AGAINST
RHEUMATOID ARTHRITIS
* SILO PHARMA INC: WE LOOK FORWARD TO OUR NEXT DATA READOUT
FOR
SPU-21 BY END OF YEAR OR EARLY 2024
Source text for Eikon: ID:nGNX2gWC1k
Further company coverage: SILO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Silo Pharma
See all newsBrief: Silo Pharma - Enters Asset Purchase Agreement With Larry King On October 13, 2026 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Norsight Consulting On Oct 1 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Parkview Consulting
Brief: Silo Pharma Selling Shareholders Offer On Resale Basis 1.9 Million Shares Of Silo Pharma Common Stock - SEC Filing
Brief: Silo Pharma Regains Compliance With Nasdaq Minimum Bid Price Requirement